Key Takeaways Expanded academic and strategic alliances, along with increased R&D, position ContextVision for market growth and stronger margins through new AI-driven imaging products. Diversification efforts in Asia and focus on disease areas with demographic growth trends support recurring revenue streams despite short-term demand challenges.Read more
ContextVision AB (publ), a software company, provides image analysis and imaging for medical systems in South Korea, China, Japan, the United States, and internationally. The company offers image quality solutions for ultrasound, as well as its Rivent platform comprising Rivent, a 2D image enhancement; Rivent Plus, a premium 2D image enhancement product; Rivent 3D, a solution for improving image quality of 3D ultrasound; and Rivent Mobile, a 2D image enhancement for handheld devices for diagnostics in various fields, including radiology, cardiology, women’s health, veterinary medicine, and point of-care applications. It also provides Altumira platform, which features scatter correction and improves radiography by enabling radiation dose reduction while enhancing image quality, such as Altumira for static applications; and Altumira Plus for dynamic applications. In addition, the company offers image quality solutions for MRI including GOPView MRI2Plus for the requirements of each application, sequence type, and protocol; and implementation projects, software updates, and upgrades and product support services. It has a strategic clinical development partnership with the University of Washington School of Medicine for collecting medical imaging data to identify a multiparametric biomarker for the screening and staging of the liver disease MASLD; and research partnership with AMRA Medical to develop AI-powered, organ-specific imaging solutions that enable MASLD screening and physiological quantification. ContextVision AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden.
